Agile Therapeutics, Inc.
101 Poor Farm Road
Princeton
New Jersey
08540
United States
Tel: 609-683-1880
Fax: 609-683-1855
Website: http://www.agiletherapeutics.com/
Email: info@agiletherapeutics.com
247 articles about Agile Therapeutics, Inc.
-
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
7/28/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022.
-
Agile Therapeutics Updates Second Quarter 2022 Guidance
7/12/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that it has updated its second quarter 2022 Twirla demand (total cycles) and operating expense (OPEX) guidance that was initially provided on May 24, 2022.
-
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
7/8/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows: Date/Time : Wednesday, July 13, 2022 at 11:00 a.m. ET.
-
As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.
-
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
7/6/2022
Agile Therapeutics, Inc., a women's healthcare company, announced the closing of its previously announced upsized public offering of an aggregate of 26,666,666 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $0.90 per share and accompanying warrants.
-
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
7/1/2022
Agile Therapeutics, Inc. announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $0.90 per share and accompanying warrants.
-
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
5/17/2022
Agile Therapeutics, Inc. will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL.
-
Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
Agile Therapeutics, Inc., a women's healthcare company, reported financial results for the three months ended March 31, 2022 and provided a corporate update.
-
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
5/5/2022
Agile Therapeutics, Inc., a women's healthcare company, publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla® transdermal system.
-
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
5/3/2022
Agile Therapeutics, Inc. today announced it will report first quarter 2022 financial results after the market close on Thursday, May 12, 2022.
-
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
4/26/2022
Agile Therapeutics, Inc., a women's healthcare company, announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022.
-
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
4/14/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Twirla prescription data for the first quarter 2022.
-
Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
4/11/2022
Agile Therapeutics, Inc. announced the receipt of $4.7 million in net proceeds from the sale of tax benefits pursuant to the Company’s participation in the New Jersey Economic Development Authority Net Operating Loss program under the New Jersey Economic Recovery Act of 2020.
-
Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)
4/7/2022
Agile Therapeutics, Inc. will be presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.
-
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
3/31/2022
Agile Therapeutics, Inc. today announced the launch of its first consumer commercial intended to increase awareness of the Twirla weekly birth control patch.
-
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
3/30/2022
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and twelve months ended December 31, 2021 and provided a corporate update.
-
Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering
3/14/2022
Agile Therapeutics, Inc. today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock.
-
Agile Therapeutics Announces $4.85 Million Registered Direct Offering
3/14/2022
Agile Therapeutics, Inc. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B convertible preferred stock and Series A warrants to purchase up to an aggregate of 24,250,000 shares of common stock and Series B warrants to purchase up to an aggregate of 24,250,000 shares of common stock.
-
Agile Therapeutics to Participate in Upcoming March 2022 Investor Events
3/11/2022
Agile Therapeutics, Inc., a women’s healthcare company, announced that Chairman and Chief Executive Officer Al Altomari will participate in two upcoming investor conferences, including a live panel discussion on drug development in Women’s Health.
-
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022Live Conference Call and Webcast at 4:30 p.m. ET
3/7/2022
Agile Therapeutics, Inc. today announced it will report fourth quarter and full year 2021 financial results after the market close on Wednesday, March 30, 2022.